

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES


Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



PATENT
ATTORNEY DOCKET NO. 50026/012003

Certificate of Mailing: Date of Deposit: May 26, 2004

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Elvis De La Cruz

Printed name of person mailing correspondence

[Signature]
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Keiwa Ozawa et al.	Art Unit:	1636
Serial No.:	09/905,592	Examiner:	R. Akhavan
Filed:	July 13, 2001	Customer No.:	21559
Title:	GENE THAT IMPARTS SELECTIVE PROLIFERATIVE ACTIVITY		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed.


Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed after a first Office Action on the merits, but before the mailing of a final Office action or a Notice of Allowance. A check for \$180.00 in payment of the late submission fee set forth in 37 C.F.R. § 1.17(p) is enclosed.

If there are any additional charges or any credits, please apply them to Deposit Account No. 03-2095.


Respectfully submitted,

Date: May 26, 2004



James D. DeCamp, Ph.D.
Reg. No. 43,580

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045



SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No. 50026/012003 Serial No. 09/905,592 Applicant Keiya Ozawa et al. Filing Date July 13, 2001 Group 1636 IDS Filed May 26, 2004		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)						
(37 C.F.R. § 1.98(b))						
U.S. PATENTS						
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Alexander et al., "Point Mutations within a Dimer Interface Homology Domain of c-Mpl Induce Constitutive Receptor Activity and Tumorigenicity," <i>The EMBO Journal</i> 14(22):5569-5578 (1995).					
	Bazan, "Structural Design and Molecular Evolution of a Cytokine Receptor Superfamily," <i>Proc. Natl. Acad. Sci. USA</i> 87:6934-6938 (1990).					
	Heldin, "Dimerization of Cell Surface Receptors in Signal Transduction," <i>Cell</i> 80:213-223 (1995).					
	Ihle, "Cytokine Receptor Signalling," <i>Nature</i> 377:591-594 (1995).					
	Murakami et al., "Critical Cytoplasmic Region of the Interleukin 6 Signal Transducer gp130 Is Conserved in the Cytokine Receptor Family," <i>Proc. Natl. Acad. Sci. USA</i> 88:11349-11353 (1991).					
	Ozawa et al., US 2002/0004582 A1, published January 10, 2002.					
	Ozawa et al., US 2003/0166161 A1, published September 04, 2003.					
	Omura et al., "Acceleration of Granulocyte Colony-Stimulating Factor-Induced Neutrophilic Nuclear Lobulation by Overexpression of Lyn Tyrosine Kinase," <i>Eur. J. Biochem.</i> 269:381-389 (2002).					
	Thornton, "Evolution of Vertebrate Steroid Receptors from an Ancestral Estrogen Receptor by Ligand Exploitation and Serial Genome Expansions," <i>Proc. Natl. Acad. Sci. USA</i> 98(10):5671-5676 (2001).					
EXAMINER				DATE CONSIDERED		
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						



PATENT
ATTORNEY DOCKET NO. 50026/012003

Certificate of Mailing: Date of Deposit: May 26, 2004

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Elvis De La Cruz

Printed name of person mailing correspondence

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Keiia Ozawa et al.	Art Unit:	1636
Serial No.:	09/905,592	Examiner:	R. Akhavan
Filed:	July 13, 2001	Customer No.:	21559
Title:	GENE THAT IMPARTS SELECTIVE PROLIFERATIVE ACTIVITY		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

COMMUNICATION REGARDING INFORMATION DISCLOSURE STATEMENT


Applicants draw the Examiner's attention to the Information Disclosure Statements ("IDSes") and Forms PTO-1449 mailed on September 19, 2002, February 19, 2004, and April 16, 2004. (Courtesy copies of these Forms PTO-1449, as filed, are enclosed.) Applicants enclose copies of the return postcards submitted with the September 19, 2002, February 19, 2004, and April 16, 2004 filings which bear the USPTO stamp indicating that the items listed on the postcard were received by the USPTO.

Applicants' file does not reflect that the Forms PTO-1449 which accompanied the September 19, 2002, February 19, 2004, and April 16, 2004 IDSes were returned with an indication that the cited references were considered by the USPTO. Applicants respectfully request that the Forms PTO-1449 be returned to Applicants with such indication.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 26 May 2004



James D. DeCamp, Ph.D.
Reg. No. 43,580

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110-2214
Telephone: 617-428-0200
Facsimile: 617-428-7045

PROSECUTION

PATENT

ATTORNEY DOCKET NUMBER: 50026/012603

The U.S. PTO date stamp sets forth the date of receipt of:

Applicant/Patentee: Keiya Ozawa et al.

Serial/Patent Number: 09/905,592


Filed/issued: July 13, 2001

Title: GENE THAT IMPARTS SELECTIVE PROLIFERATIVE ACTIVITY

<input type="checkbox"/> Transmittal Letter	Pages: _____	<input type="checkbox"/> Declaration & POA	Pages: _____
<input type="checkbox"/> Notice of Missing Parts	Pages: _____	<input type="checkbox"/> Assignment & Cover Sheet	Pages: _____
<input type="checkbox"/> Reply to Missing Parts	Pages: _____	<input type="checkbox"/> Change of Address	Pages: _____
<input type="checkbox"/> Reply to Examiner's Action	Pages: _____	<input type="checkbox"/> Small Entity Statement	Pages: _____
<input type="checkbox"/> Extension of Time	Pages: _____	<input type="checkbox"/> Preliminary Amendment	Pages: 2
<input type="checkbox"/> Notice of Appeal	Pages: _____	<input checked="" type="checkbox"/> IDS - Supplemental	Pages: 6
<input type="checkbox"/> Appeal Brief	Pages: _____	<input checked="" type="checkbox"/> Cited References	Number: 6
<input type="checkbox"/> Drawings Formal/Informal	Pages: _____	<input checked="" type="checkbox"/> Other Communication from	Pages: 2
<input type="checkbox"/> M-Fee Payment	Pages: _____	<input checked="" type="checkbox"/> foreign patent office	Pages: _____
<input type="checkbox"/> Issue Fee Payment	Pages: _____	<input type="checkbox"/> Other	Pages: _____
<input type="checkbox"/> Check	\$: _____		
<input type="checkbox"/> Other	Pages: _____		

Atty/Secy: JDD:JNT Client/Matter Name: Shimizu Date: 9-19-02
(eef)

(eef)





Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No.		50026/012003	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. §1.98(b))				Serial No.		09/905,592	
				Applicant		Keiya Ozawa et al.	
				Filing Date		July 13, 2001	
				Group		1655	
				IDS Filed		September 19, 2002	
U.S. PATENTS							
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)	
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION							
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)	
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)							
	Chan et al., "A Murine Cytokine Fusion Toxin Specifically Targeting the Murine Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Receptor on Normal Committed Bone Marrow Progenitor Cells and GM-CSF-Dependent Tumor Cells," <i>Blood</i> 86:2732-2740 (1995).						
	Ito et al., "G-CSFR-Estrogen-R Fusion cDNA as a Novel Selective Amplifier Gene for Controllable Expansion of Transduced Hematopoietic Stem Cells," (Abstract 538) <i>Blood</i> 88:137A (1996).						
	Jackson et al., "Hormone-Conditional Transformation by Fusion Proteins of c-Abl and its Transforming Variants," <i>EMBO J</i> 12:2809-2819 (1993).						
	Nagata and Fukunaga, "Granulocyte Colony-Stimulating Factor and its Receptor," <i>Prog. Growth Factor Res.</i> , 3:131-141 (1991).						
	Ozawa et al., "Development of a Novel Selective Amplifier Gene for <i>In Vivo</i> Selective Expansion of Transduced Hematopoietic Stem Cells," (Abstract 161) <i>Experimental Hematology</i> 24:1053 (1996).						
	Williams and Park, "Hematopoietic Effects of a Granulocyte-Macrophage Colony-Stimulating Factor/Interleukin-3 Fusion Protein," <i>Cancer</i> 67(Supplement):2705-2707 (1991).						
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.							

****PROSECUTION****

PATENT
ATTORNEY DOCKET NUMBER: 50026/012003


The U.S. PTO date stamp sets forth the date of receipt of:

Applicant/Patentee: OZAWA ET AL.

Serial/Patent Number: 09/905,592

Filed/Issued: JULY 13, 2001

Title: GENE THAT IMPARTS SELECTIVE PROLIFERATIVE ACTIVITY



<input type="checkbox"/> Transmittal Letter	Pages: _____	<input type="checkbox"/> Declaration & POA	Pages: _____
<input type="checkbox"/> Notice to File Missing Parts	Pages: _____	<input type="checkbox"/> Assignment & Cover Sheet	Pages: _____
<input type="checkbox"/> Reply to Missing Parts	Pages: _____	<input type="checkbox"/> Change of Address	Pages: _____
<input type="checkbox"/> Reply to Office Action	Pages: _____	<input type="checkbox"/> Preliminary Amendment	Pages: _____
<input type="checkbox"/> Petition for Extension	Pages: _____	<input checked="" type="checkbox"/> IDS (SUPPLEMENTAL)	Pages: 2
<input type="checkbox"/> Notice of Appeal	Pages: _____	<input checked="" type="checkbox"/> Form PTO-1449	Pages: 1
<input type="checkbox"/> Appeal Brief	Pages: _____	<input checked="" type="checkbox"/> Cited References	Number: 12
<input type="checkbox"/> Drawings Formal/Informal	Pages: _____	<input type="checkbox"/> Sequence Listing	Pages: _____
<input type="checkbox"/> M-Fee Payment	Pages: _____	<input type="checkbox"/> Sequence Statement	Pages: _____
<input type="checkbox"/> Issue Fee Payment	Pages: _____	<input type="checkbox"/> Sequence Diskette	Number: _____
<input checked="" type="checkbox"/> Check	\$: 180.00	<input type="checkbox"/> Other	Pages: _____
<input type="checkbox"/> Other	_____	<input type="checkbox"/> Other	Pages: _____
<input type="checkbox"/> Other	_____	<input type="checkbox"/> Other	Pages: _____
<input type="checkbox"/> Other	_____	<input type="checkbox"/> Other	Pages: _____

Att/Secy: JDD / JNT / c Client/Matter Name: _____ Date: 2/19/04





SUBSTITUTE FORM PTO-1449 (MODIFIED) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50026/012003
		Serial No.	09/905,592
		Applicant	Keiya Ozawa et al.
		Filing Date	July 13, 2001
		Group	1636
		IDS Filed	February 19, 2004

U.S. PATENTS

Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

	Anderson, "Human Gene Therapy" <i>Nature</i> 392(Supp.):25-30 (1998).
	Cheok, "Cancer Fears Cast Doubts on Future of Gene Therapy" <i>Nature</i> 421:678 (2003).
	Cui et al., "Inhibitory Effect of a Soluble Transforming Growth Factor β Type II Receptor on the Activation of Rat Hepatic Stellate Cells in Primary Culture" <i>Journal of Hepatology</i> 39:731-737 (2003).
	Juengst, "What Next for Human Gene Therapy" <i>BMJ</i> 326:1410-1411 (2003).
	Kakuta et al., "Inhibition of B16 Melanoma Experimental Metastasis by Interferon- γ through Direct Inhibition of Cell Proliferation and Activation of Antitumour Host Mechanisms," <i>Immunology</i> 105:92-100 (2002).
	Kmieć "Gene Therapy" <i>American Scientist</i> 87:240-247 (1999).
	Marcinkowska and Więdołcha "Steroid Signal Transduction Activated at the Cell Membrane: from Plants to Animals," <i>Acta Biochimica Polonica</i> 49(3):735-745 (2002).
	Maruyama et al., "Proliferation and Erythroid Differentiation through the Cytoplasmic Domain of the Erythropoietin Receptor," <i>The Journal of Biological Chemistry</i> , 269(8):5976-5980 (1994).
	O'Farrell et al., "IL-10 Inhibits Macrophage Activation and Proliferation by Distinct Signaling Mechanisms: Evidence for Stat3-Dependent and -Independent Pathways," <i>The EMBO Journal</i> 17(4):1006-1018 (1998).
	Verma and Somia, "Gene Therapy-Promises, Problems and Prospects," <i>Nature</i> 389:239-242 (1997).
	Wang et al., "Yeast Two-Hybrid System Demonstrates that Estrogen Receptor Dimerization Is Ligand-Dependent <i>in Vivo</i> ," <i>The Journal of Biological Chemistry</i> , 270(40):23322-23329 (1995).
	Wimmel et al., "Autocrine Growth Inhibition by Transforming Growth Factor β -1 (TGF β -1) in Human Neuroendocrine Tumour Cells," <i>Gut</i> 52:1308-1316 (2003).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.



****PROSECUTION****

PATENT
ATTORNEY DOCKET NUMBER: 50026/012003

The U.S. PTO date stamp sets forth the date of receipt of:

Applicant/Patentee: OZAWA ET AL.

Serial/Patent Number: 09/905,592

Filed/Issued: JULY 13, 2001

Title: GENE THAT IMPARTS SELECTIVE PROLIFERATIVE ACTIVITY

☐ Transmittal Letter

Pages: _____

☐ Declaration & POA

Pages: _____

☐ Notice to File Missing Parts

Pages: _____

☐ Assignment & Cover Sheet

Pages: _____

☐ Reply to Missing Parts

Pages: _____

☐ Change of Address

Pages: _____

☐ Reply to Office Action

Pages: _____

☐ Preliminary Amendment

Pages: _____

☐ Petition for Extension

Pages: _____

☒ IDS (Supplemental)

Pages: 2

☐ Notice of Appeal

Pages: _____

☒ Form PTO-1449

Pages: 1

☐ Appeal Brief

Pages: _____

☒ Cited References

Number: 2

☐ Drawings Formal/Informal

Pages: _____

☐ Sequence Listing

Pages: _____

☐ M-Fee Payment

Pages: _____

☐ Sequence Statement

Pages: _____

☒ Issue Fee Payment

Pages: _____

☐ Sequence Diskette

Pages: _____

☒ Check

\$: 180.00

☐ Other _____

Pages: _____

☐ Other _____

Pages: _____

☐ Other _____

Pages: _____

☐ Other _____

Pages: _____

☐ Other _____

Pages: _____

Att/Secy: JDD/JNT/c Client/Matter Name: _____

Date: 4/16/04





Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No.		50026/012003	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Serial No.		09/905,592	
				Applicant		Keiya Ozawa et al.	
				Filing Date		July 13, 2001	
				Group		1636	
				IDS Filed		April 16, 2004	
(37 C.F.R. §1.98(b))							
U.S. PATENTS							
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)	
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION							
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)	
	WO 93/10151	May 27, 1993	WIPO				
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)							
	Gearing et al., "The IL-6 Signal Transducer, gp130: An Oncostatin M Receptor and Affinity Converter for the LIF Receptor," <i>Science</i> 255(5050):1434-1437 (1992).						
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.							